ElevateBio
Provides integrated discovery platforms, R&D services, and end-to-end process development and cGMP manufacturing for cell and gene therapies, mRNA therapeutics, and related modalities. Capabilities include gene editing discovery and engineering, AI/ML-enabled design workflows, delivery and formulation development, sequencing-based analytics and analytical method development, process development and technology transfer, digital manufacturing execution and traceability systems, automation-enabled closed bioprocessing, and regulatory CMC support. Operates multiple purpose-built facilities and pursues strategic partnerships and cloud collaborations to support scale-up and accelerated development.
Industries
Nr. of Employees
large (251-1000)
Services
End-to-end GMP manufacture of cell therapies, viral vectors and mRNA from clinical supply through commercial scale.
Discovery and engineering services across multiple editing modalities including candidate screening, enzyme and guide RNA engineering, specificity assessment, model selection and lead optimization for IND-enabling programs.
Process development, optimization, characterization and industrialization services designed to create scalable, GMP-compatible processes and to support efficient technology transfer into manufacturing.
Custom analytical assay development, sequencing-based contaminant detection and bioinformatics services to support characterization, investigations and accelerated lot release strategies.
Regulatory strategy and CMC advisory services including PPQ planning, inspection readiness, regulatory submission support and lifecycle-aligned CMC design.
Structuring of strategic research collaborations, licensing agreements and co-development arrangements to provide partners access to discovery platforms, manufacturing capacity and technical expertise.
End-to-end GMP manufacture of cell therapies, viral vectors and mRNA from clinical supply through commercial scale.
Discovery and engineering services across multiple editing modalities including candidate screening, enzyme and guide RNA engineering, specificity assessment, model selection and lead optimization for IND-enabling programs.
Process development, optimization, characterization and industrialization services designed to create scalable, GMP-compatible processes and to support efficient technology transfer into manufacturing.
Custom analytical assay development, sequencing-based contaminant detection and bioinformatics services to support characterization, investigations and accelerated lot release strategies.
Regulatory strategy and CMC advisory services including PPQ planning, inspection readiness, regulatory submission support and lifecycle-aligned CMC design.
Structuring of strategic research collaborations, licensing agreements and co-development arrangements to provide partners access to discovery platforms, manufacturing capacity and technical expertise.
Expertise Areas
- Advanced therapy process development and technology transfer
- cGMP manufacturing for cell, viral vector and mRNA modalities
- Gene editing discovery and protein/gRNA engineering
- AI/ML-enabled design for gene editing and protein engineering
Key Technologies
- Next-generation sequencing (NGS)
- Targeted enrichment and unbiased sequencing workflows
- Bioinformatics pipelines for off-target and contaminant detection
- Lipid nanoparticle formulation
News & Updates
Announcement of a multi-million dollar commitment to launch a rare disease acceleration platform in collaboration with regional partners.
Podcast/interview discussing multi-modality gene editing discovery and platform strategy.
Article discussing approaches to scale gene editing and pursue generalizable therapies.
Profile of a manufacturing site presented as an example for scaling biomanufacturing capacity in the U.S.
Opinion piece referencing regional manufacturing investment and the company's role in local biotech development.
Profile summarizing funding and facility expansion to increase manufacturing capacity.
Announcement of a multi-million dollar commitment to launch a rare disease acceleration platform in collaboration with regional partners.
Podcast/interview discussing multi-modality gene editing discovery and platform strategy.
Article discussing approaches to scale gene editing and pursue generalizable therapies.
Profile of a manufacturing site presented as an example for scaling biomanufacturing capacity in the U.S.
Opinion piece referencing regional manufacturing investment and the company's role in local biotech development.
Profile summarizing funding and facility expansion to increase manufacturing capacity.